Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA reduced its stake in Regeneron Pharmaceuticals by 90.8%, leaving it with only 148 shares valued at $87,000 after selling 1,452 shares during the first quarter.
• Other major investors, including Vanguard Group and Goldman Sachs, increased their positions in Regeneron, highlighting strong institutional interest, with 83.31% of the stock owned by institutional investors.
• Regeneron Pharmaceuticals recently reported better-than-expected quarterly earnings, with $12.89 earnings per share, exceeding analysts’ estimates of $8.43, and a revenue of $3.68 billion for the quarter.

Banque Transatlantique SA trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 90.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 148 shares of the biopharmaceutical company's stock after selling 1,452 shares during the period. Banque Transatlantique SA's holdings in Regeneron Pharmaceuticals were worth $87,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Amundi lifted its stake in Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after purchasing an additional 52,166 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Finally, Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Up 1.1%

Regeneron Pharmaceuticals stock opened at $573.38 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,170.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a market cap of $60.77 billion, a PE ratio of 14.45, a P/E/G ratio of 1.90 and a beta of 0.35. The stock's fifty day moving average is $562.59 and its two-hundred day moving average is $584.62.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the firm earned $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.